Tovorafenib

Brand names: Ojemda · Active ingredient: Tovorafenib

In short: OJEMDA is indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. This indication is approved under accelerated approval based on response rate and duration of resp

Forms & strengthsTablets: 100 mg: orange, film-coated, oval tablets debossed with "100"; on one side and "D101" on the opposite side. Each tablet contains 100 mg of tovorafenib. For Oral Suspension: 25 mg/mL: white to off white powder. …
LabelDay One Biopharmaceuticals, Inc.
Label updatedSep 08, 2025

What is Tovorafenib used for?

OJEMDA is indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.

This indication is approved under accelerated approval based on response rate and duration of response . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Tovorafenib dosage

Select patients for treatment with OJEMDA based on the presence of BRAF fusion or rearrangement, or BRAF V600 mutation in tumor specimens .

Information on FDA-approved tests for the detection of BRAF fusions, BRAF rearrangements, and BRAF V600 mutations is available at http://www.fda.gov/companiondiagnostics.

Before initiating OJEMDA, evaluate liver function tests, including ALT, AST and bilirubin .

The recommended dosage of OJEMDA based on body surface area (BSA) is 380 mg/m2 orally once weekly (the maximum recommended dosage is 600 mg orally once weekly) with or without food until disease progression or intolerable toxicity. OJEMDA may be administered as an immediate release tablet or as an oral suspension . A recommended dosage for patients with BSA less than 0.3 m2 has not been established.

Body Surface Area (m2) | Recommended Dosage

0.30-0.89 | Administer OJEMDA oral suspension once weekly

0.90-1.12 | 400 mg once weekly

1.13-1.39 | 500 mg once weekly

≥ 1.40 | 600 mg once weekly

Body Surface Area (m2) | Dose Volume (mL)OJEMDA for oral suspension has a concentration of 25 mg/mL. Each bottle of OJEMDA for oral suspension delivers 300 mg/12 mL. | Dosage

0.30-0.35 | 5 | 125 mg once weekly

0.36-0.42 | 6 | 150 mg once weekly

0.43-0.48 | 7 | 175 mg once weekly

0.49-0.54 | 8 | 200 mg once weekly

0.55-0.63 | 9 | 225 mg once weekly

0.64-0.77 | 11 | 275 mg once weekly

0.78-0.83 | 12 | 300 mg once weekly

0.84-0.89 | 14 | 350 mg once weekly

0.90-1.05 | 15 | 375 mg once weekly

1.06-1.25 | 18 | 450 mg once weekly

1.26-1.39 | 21 | 525 mg once weekly

≥1.40 | 24 | 600 mg once weekly

Continue once weekly dosing until disease progression or intolerable toxicity.

Take OJEMDA at a regularly scheduled time once weekly.

OJEMDA may be taken with or without food .

If a dose is missed by:

3 days or less, take the missed dose as soon as possible, and take the next dose on its regularly scheduled day.

more than 3 days, skip the missed dose and take the next dose on its regularly scheduled day.

If vomiting occurs immediately after taking a dose, repeat that dose.

OJEMDA tablets

Swallow tablets whole with water.

Do not chew, cut, or crush.

OJEMDA for oral suspension

Prior to first time use of OJEMDA for oral suspension, ensure that caregivers (and if appropriate, patients) read and understand the "Instructions for Use" before preparing, measuring, and administering OJEMDA.

Preparation and Administration

Reconstitute the powder in each supplied bottle with exactly 14 mL of room temperature water to form the OJEMDA for oral suspension. After reconstitution each mL contains 25 mg of tovorafenib. Product foaming after reconstitution reduces the deliverable volume.

Each bottle delivers 300 mg of tovorafenib in 12 mL. …

How to take Tovorafenib — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Hemorrhage

Advise patients that OJEMDA can cause bleeding and to contact their healthcare provider for signs or symptoms of bleeding .

Skin Toxicities

Advise patients that OJEMDA can cause skin toxicities and to contact their healthcare provider for worsening or intolerable rash .

Photosensitivity

Advise patients that OJEMDA can cause photosensitivity. Advise patients to limit direct ultraviolet exposure during treatment with OJEMDA. Recommend that patients use precautionary measures such as use of sunscreen, sunglasses, and/or protective clothing during treatment with OJEMDA .

Hepatotoxicity

Advise patients that OJEMDA can cause liver toxicity and to contact their healthcare provider for signs or symptoms of liver dysfunction. Advise patients that serial testing of serum liver tests (ALT, AST, bilirubin) is recommended during treatment with OJEMDA .

Effect on Growth

Advise patients and caregivers that treatment with OJEMDA may cause a reduction in growth velocity, and that growth will be monitored during treatment with OJEMDA . …

Warnings & precautions

Do not take this medicine if: None.

Hemorrhage, including major hemorrhage defined as symptomatic bleeding in a critical area or organ, can occur with OJEMDA. In the pooled safety population , hemorrhagic events occurred in 37% of patients, including epistaxis in 26% and intratumoral hemorrhage in 9%. Serious events of bleeding occurred in 5% of patients including Grade 5 tumor hemorrhage in 1 patient (0.6%). OJEMDA was permanently discontinued for hemorrhage in 2% of patients.

Advise patients and caregivers of the risk of hemorrhage during treatment with OJEMDA. Monitor for signs and symptoms of hemorrhage and evaluate as clinically indicated. Withhold and resume at reduced dose upon improvement, or permanently discontinue based on severity .

OJEMDA can cause rash, including maculopapular rash and photosensitivity. In the pooled safety population , rash occurred in 67% of patients treated with OJEMDA, including Grade 3 rash in 12%. Rash resulted in dose interruption in 15% of patients and dose reduction in 7% of patients. OJEMDA was permanently discontinued due to rash in 1% of patients (n=2). In the pooled safety population, dermatitis acneiform occurred in 26% of patients treated with OJEMDA, including Grade 3 dermatitis acneiform in 0.6% of patients (n=1). Dose reduction was required in 2% of patients (n=3) due to dermatitis acneiform.

Monitor for new or worsening skin reactions. Consider dermatologic consultation and initiate supportive care as clinically indicated. Withhold, reduce the dose, or permanently discontinue OJEMDA based on severity of adverse reaction .

Photosensitivity

In the pooled safety population , photosensitivity occurred in 12% of patients treated with OJEMDA, including Grade 3 events in 0.6% of patients (n=1). …

Tovorafenib side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

Hemorrhage

Skin Toxicity Including Photosensitivity

Hepatotoxicity

Effect on Growth

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety population described in WARNINGS AND PRECAUTIONS reflects exposure to OJEMDA taken orally once weekly at a dose based on body surface area in 140 patients with relapsed or refractory pediatric LGG or advanced solid tumors harboring a RAF alteration and a flat dose of 600 mg in 32 adult patients with advanced solid tumors until disease progression or intolerable toxicity. Among 172 patients treated with OJEMDA, 86% were exposed for 6 months or longer and 49% were exposed for 1 year or longer.

Pediatric Low-grade Glioma

The safety of OJEMDA was evaluated in 137 patients with relapsed or refractory pediatric LGG harboring a BRAF alteration in FIREFLY-1 (Arms 1 and 2) . Patients received OJEMDA at a dose based on body surface area orally once weekly until disease progression or intolerable toxicity. …

Drug interactions

Table 8 describes drug interactions where coadministration with another drug affects OJEMDA.

Strong or Moderate CYP2C8 Inhibitors

Prevention or Management | Avoid coadministration of OJEMDA with a strong or moderate CYP2C8 inhibitor.

Mechanism and Clinical Effect(s) | Tovorafenib is a CYP2C8 substrate. Strong or moderate CYP2C8 inhibitors are predicted to increase tovorafenib exposure based on a mechanistic understanding of its elimination , which may increase the risk of adverse reactions with OJEMDA.

Strong or Moderate CYP2C8 Inducers

Prevention or Management | Avoid coadministration of OJEMDA with a strong or moderate CYP2C8 inducer.

Mechanism and Clinical Effect(s) | Tovorafenib is a CYP2C8 substrate. Strong or moderate CYP2C8 inducers are predicted to decrease tovorafenib exposure based on a mechanistic understanding of its elimination , which may reduce the effectiveness of OJEMDA.

Table 9 describes drug interactions where coadministration with OJEMDA affects another drug.

CYP3A Substrates

Prevention or Management | Hormonal Contraceptives: Avoid coadministration of hormonal contraceptives with OJEMDA. If coadministration is unavoidable, use an additional effective nonhormonal contraceptive method during coadministration and for 28 days after discontinuation of OJEMDA. …

About this medicine

OJEMDA contains tovorafenib, a kinase inhibitor. Tovorafenib has the molecular formula C17H12Cl2F3N7O2S and a molecular weight of 506.29. The chemical name for tovorafenib is 6-amino-5-chloro-N-[(1R)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2-pyridinyl]amino]carbonyl]-2-thiazolyl]ethyl]-4-pyrimidinecarboxamide. Tovorafenib has the following chemical structure:

It is a white to off-white powder. The solubility of tovorafenib at 37ºC is ≤ 3 micrograms/mL from pH 1.2 to 8 in aqueous media.

OJEMDA (tovorafenib) tablets are supplied as 100 mg strength tablets for oral administration. Each tablet contains 100 mg tovorafenib and the following inactive ingredients: copovidone, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and orange film coating (hypromellose, polyethylene glycol 8000, titanium dioxide, ferric oxide yellow, ferric oxide red).

OJEMDA (tovorafenib) for oral suspension is a white to off white powder which produces a white suspension when reconstituted with water. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID ea3a9631-3a66-6a7c-e053-2995a90ae2ad. Read the full official label on DailyMed.